SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors [Yahoo! Fina...
SpringWorks Therapeutics, Inc. - common stock (SWTX)
Last springworks therapeutics, inc. - common stock earnings: 3/12 04:30 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
to placebo, with rapid and sustained improvements in symptom burden including pain, physical and role functioning, and quality of life STAMFORD, Conn., Feb. 29, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for nirogacestat, an oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors. If approved, nirogacestat will be the first therapy to receive marketing authorization in the European Union (EU) for the treatment of desmoid tumors. Nirogacestat previously received Orphan Drug designation from the European Commission for the treatment of soft tissue sarcoma. “The validation of our marketing authorization application is an important step towards bringing nirogacestat to patients with desmoid tumors in the European Union who current
Show less
Read more
Impact Snapshot
Event Time:
SWTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SWTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SWTX alerts
High impacting SpringWorks Therapeutics, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
SWTX
News
- SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $74.00 price target on the stock.MarketBeat
- SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire
- SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference [Yahoo! Finance]Yahoo! Finance
- SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care ConferenceGlobeNewswire
SWTX
Earnings
- 5/2/24 - Beat
SWTX
Sec Filings
- 6/3/24 - Form 144
- 6/3/24 - Form 144
- 6/3/24 - Form 144
- SWTX's page on the SEC website